



# HYDROXYCHLOROQUINE

**Effective and safe treatment option in the management of Lupus & Rheumatoid arthritis**



## General Information

Name: Hydroxychloroquine Rubiò®  
API: Hydroxychloroquine Sulfate  
Presentation: 200 mg x 30 film-coated tablets packaged in Blister

## Indications

- Rheumatoid Arthritis (joints inflammation)
- Treatment of non-acute and non-complicated Malaria attacks and prevention of Malaria
- Systemic and discoid Lupus Erythematosus (skin or internal organs illness)

## Competitive Advantages

- Coated tablets which allows better patient swallowing.
- Rubiò is the leader in Spain with 95% of market share with this molecule.

## Registration and Marketing Authorization

- Rubiò has marketed this molecule in Spain since 2002
- To be registered as Generic of the originator (Plaquenil®, Sanofi's Reference Product). Bioequivalence (BE) study with Plaquenil® will be available in the CTD file ready in Q4 2025.
- Rubiò markets this molecule in DO, ES, IQ, LB & RS.

## Deal Design

- Deal design consisting of an Exclusive Licensing & Supply/Distribution Agreement to market the Finished Product manufactured by Laboratorios Rubiò,S.A.
- We are searching for the best Partner to develop trustful, fruitful and long-term business partnerships.

**Rubiò** 55  
years

**We are pharmacypathfinders**

### Founded

1968

### Location

Castellbisbal, Barcelona, Spain

### Main Focus

CNS, Nephrology/Urology, Cardiovascular, Gastroenterology, Rheumatology/Orthopedic, Oncology/Radiotherapy, Gynecology.

### About Rubiò

For 55 years Laboratorios Rubiò, a family-owned company, has been recognized for the development, manufacture and marketing of medicines with high therapeutic value for specialists as well as of certain drugs for life-threatening diseases, with long expertise in niche markets.

Laboratorios Rubiò's determination to meet the health needs of every single patient has led the company to be distinguished as per being pioneer of products targeted to low incidence diseases which affect only a small number of patients and that require the development of specific pharmaceutical products to treat them.

### International Alliances and Partnering Strategy

Laboratorios Rubiò has established a strong network of partnerships through in and out activities and commercial distribution agreements. Laboratorios Rubiò has been in the export business since 1982 and has alliances in over 60 countries. Laboratorios Rubiò is constantly exploring new territories and partnerships.

### Contact details:

Laboratorios Rubiò, S.A.  
Industria 29, P.I. Comte de Sert  
08755 Castellbisbal, Barcelona, Spain  
Tel.: +34 937 722 509  
Fax: +34 937 721 602  
[www.laboratoriosrubio.com](http://www.laboratoriosrubio.com)

### Contact:

[export@labrubio.com](mailto:export@labrubio.com)